Advanced search
Publication Cover
International Journal of General Medicine Volume 14, 2021 - Issue
Submit an article Journal homepage
106
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study

Hong-Tao JiangDepartment of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of China
,
Wei LiDepartment of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of China
,
Biao ZhangDepartment of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of China
,
Qiang GongDepartment of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of China
&
Hai-Ling QieDepartment of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, 071000, People’s Republic of ChinaCorrespondence[email protected] [email protected]
Pages 7625-7637 | Published online: 02 Nov 2021

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Chen Hong, Jianping Wei, Tao Zhou, Xia Wang & Jing Cai. (2022) FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib. OncoTargets and Therapy 15, pages 651-657.
Read now
Song Zhang, Xin Wang, Hao Gu & Jun-Qi Liu. (2022) Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study. Cancer Management and Research 14, pages 1715-1727.
Read now

Articles from other publishers (2)

Xiao-Ping Li, Wei-Dong Zhang, Ming-Jiang Li, Juan Wang, Jie Lian & Hong-Gang Zhou. (2022) Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study. Journal of Oncology 2022, pages 1-10.
Crossref
Bo Cao, Shiyuan Wang, Ruisheng Li, Zhihong Wang, Taifeng Li, Yuanyuan Zhang, Bin Dong, Yingying Li, Mengmeng Lin, Xingjie Li, Xiaohe Xiao, Chunyu Li & Guohui Li. (2022) Xihuang Pill enhances anticancer effect of anlotinib by regulating gut microbiota composition and tumor angiogenesis pathway. Biomedicine & Pharmacotherapy 151, pages 113081.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.